Literature DB >> 34812840

Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment.

Yakir Rottenberg1,2, Albert Grinshpun3, Iddo Z Ben-Dov4,2, Esther Oiknine Djian5,2, Dana G Wolf5,2, Luna Kadouri1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34812840      PMCID： PMC8611511          DOI： 10.1001/jamaoncol.2021.6764

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  12 in total

1.  Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.

Authors:  Michael A Thompson; Sigrun Hallmeyer; Veronica E Fitzpatrick; Yunqi Liao; Michael P Mullane; Stephen C Medlin; Kenneth Copeland; James L Weese
Journal:  J Patient Cent Res Rev       Date:  2022-07-18

Review 2.  Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.

Authors:  Arielle Elkrief; Julie T Wu; Chinmay Jani; Kyle T Enriquez; Michael Glover; Mansi R Shah; Hira Ghazal Shaikh; Alicia Beeghly-Fadiel; Benjamin French; Sachin R Jhawar; Douglas B Johnson; Rana R McKay; Donna R Rivera; Daniel Y Reuben; Surbhi Shah; Stacey L Tinianov; Donald Cuong Vinh; Sanjay Mishra; Jeremy L Warner
Journal:  Cancer Discov       Date:  2021-12-10       Impact factor: 38.272

3.  Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine.

Authors:  Bruna Lo Sasso; Luisa Agnello; Rosaria Vincenza Giglio; Caterina Maria Gambino; Anna Maria Ciaccio; Matteo Vidali; Marcello Ciaccio
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

4.  Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.

Authors:  Takashi Kobayashi
Journal:  Int J Urol       Date:  2022-04-27       Impact factor: 2.896

5.  Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.

Authors:  Shirley Shapiro Ben David; Barak Mizrahi; Daniella Rahamim-Cohen; Lia Supino-Rosin; Arnon Shahar; Sharon Hermoni-Alon; Ariela Fremder Sacerdote; Angela Irony; Rachel Lazar; Nir Kalkstein; Yaniv Lustig; Victoria Indenbaum; Daniel Landsberger; Miri Mizrahi-Reuveni; Shirley Shapira
Journal:  Vaccine       Date:  2022-05-28       Impact factor: 4.169

Review 6.  Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.

Authors:  Aaron Shengting Mai; Ainsley Ryan Yan Bin Lee; Ryan Yong Kiat Tay; Lauren Shapiro; Astha Thakkar; Balazs Halmos; Albert Grinshpun; Yair Herishanu; Ohad Benjamini; Tamar Tadmor; Rachna T Shroff; Bonnie J LaFleur; Deepta Bhattacharya; Siyu Peng; Jeremy Tey; Soo Chin Lee; Louis Yi Ann Chai; Yu Yang Soon; Raghav Sundar; Matilda Xinwei Lee
Journal:  Eur J Cancer       Date:  2022-06-03       Impact factor: 10.002

7.  Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer.

Authors:  V Di Noia; F Pimpinelli; D Renna; M T Maccallini; L Gariazzo; F Riva; E Sperandio; D Giannarelli; F Cognetti
Journal:  Ann Oncol       Date:  2022-02-22       Impact factor: 51.769

8.  Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.

Authors:  A Lasagna; F Bergami; D Lilleri; E Percivalle; M Quaccini; N Alessio; G Comolli; A Sarasini; J C Sammartino; A Ferrari; F Arena; S Secondino; D Cicognini; R Schiavo; G Lo Cascio; L Cavanna; F Baldanti; P Pedrazzoli; I Cassaniti
Journal:  ESMO Open       Date:  2022-03-11

9.  Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.

Authors:  Alessandra Vergori; Alessandro Cozzi Lepri; Stefania Cicalini; Giulia Matusali; Veronica Bordoni; Simone Lanini; Silvia Meschi; Roberta Iannazzo; Valentina Mazzotta; Francesca Colavita; Ilaria Mastrorosa; Eleonora Cimini; Davide Mariotti; Lydia De Pascale; Alessandra Marani; Paola Gallì; AnnaRosa Garbuglia; Concetta Castilletti; Vincenzo Puro; Chiara Agrati; Enrico Girardi; Francesco Vaia; Andrea Antinori
Journal:  Nat Commun       Date:  2022-08-22       Impact factor: 17.694

Review 10.  COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.

Authors:  Annika Fendler; Elisabeth G E de Vries; Corine H GeurtsvanKessel; John B Haanen; Bernhard Wörmann; Samra Turajlic; Marie von Lilienfeld-Toal
Journal:  Nat Rev Clin Oncol       Date:  2022-03-11       Impact factor: 65.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.